Automated Intracytoplasmic Sperm Injection (ICSIA)
Launched by OVERTURE LIFE · Nov 21, 2022
Trial Information
Current as of May 05, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new system called the Automated Intracytoplasmic Sperm Injection (ICSIA) used during in vitro fertilization (IVF) to help women who are having trouble getting pregnant. The ICSIA system aims to make the process of injecting sperm into eggs more efficient by automating the procedure. Researchers will compare the success rates of fertilization and the health of the eggs when using this automated system versus the traditional manual method.
To be eligible for this trial, women must be between the ages of 18 and 62 and undergoing IVF treatment that includes a method called ICSI, which is specifically for cases of infertility. However, women with severe male infertility issues will not be able to participate. If you join the study, you'll be part of a process that could potentially improve fertility treatments for others in the future. Currently, the trial is active but not recruiting new participants, which means they are not looking for new people to join right now.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Infertile women undergoing IVF treatment with ICSI
- Exclusion Criteria:
- • Severe male factor infertility
About Overture Life
Overture Life is a pioneering clinical trial sponsor dedicated to advancing reproductive health and fertility solutions through innovative research and development. By leveraging cutting-edge technologies and a patient-centered approach, Overture Life aims to enhance the efficacy and accessibility of fertility treatments. The organization collaborates with leading healthcare professionals and research institutions to conduct clinical trials that prioritize safety, ethical standards, and scientific rigor, ultimately striving to improve outcomes for individuals and couples seeking to build their families. With a commitment to transparency and collaboration, Overture Life is at the forefront of transforming the landscape of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
John Zhang, MD
Principal Investigator
New Hope Fertility Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials